Prelude Therapeutics Inc (NASDAQ: PRLD) kicked off on Monday, down -9.70% from the previous trading day, before settling in for the closing price of $1.34. Over the past 52 weeks, PRLD has traded in a range of $0.80-$6.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 12.13%. With a float of $21.68 million, this company’s outstanding shares have now reached $42.18 million.
The extent of productivity of a business whose workforce counts for 128 workers is very important to gauge. In terms of profitability, gross margin is 81.18%, operating margin of -2230.11%, and the pretax margin is -2047.28%.
Prelude Therapeutics Inc (PRLD) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 60.49%, while institutional ownership is 35.27%. The most recent insider transaction that took place on Dec 23 ’24, was worth 82,002. In this transaction Chief Chemistry Officer of this company bought 60,000 shares at a rate of $1.37, taking the stock ownership to the 377,623 shares. Before that another transaction happened on Dec 20 ’24, when Company’s Chief Chemistry Officer bought 3,075 for $1.15, making the entire transaction worth $3,536. This insider now owns 317,623 shares in total.
Prelude Therapeutics Inc (PRLD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.10% during the next five years compared to -43.14% drop over the previous five years of trading.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Take a look at Prelude Therapeutics Inc’s (PRLD) current performance indicators. Last quarter, stock had a quick ratio of 7.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
The latest stats from [Prelude Therapeutics Inc, PRLD] show that its last 5-days average volume of 0.69 million was superior to 0.22 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 64.40%. Additionally, its Average True Range was 0.16.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 6.89%, which indicates a significant decrease from 52.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 198.08% in the past 14 days, which was higher than the 144.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1632, while its 200-day Moving Average is $3.4187. Now, the first resistance to watch is $1.3520. This is followed by the second major resistance level at $1.4940. The third major resistance level sits at $1.6100. If the price goes on to break the first support level at $1.0940, it is likely to go to the next support level at $0.9780. The third support level lies at $0.8360 if the price breaches the second support level.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
The company with the Market Capitalisation of 63.74 million has total of 55,035K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -121,830 K annual income. Company’s last quarter sales were recorded 3,000 K and last quarter income was -32,270 K.
